The estimated Net Worth of Charles F Jr Wagner is at least $36.5 Million dollars as of 3 June 2024. Mr. Wagner owns over 3,250 units of Vertex Pharmaceuticals stock worth over $22,377,819 and over the last 14 years he sold VRTX stock worth over $10,625,928. In addition, he makes $3,487,210 as Chief Financial Officer and Executive Vice President at Vertex Pharmaceuticals.
Charles has made over 13 trades of the Vertex Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 3,250 units of VRTX stock worth $1,495,000 on 3 June 2024.
The largest trade he's ever made was selling 19,000 units of Vertex Pharmaceuticals stock on 17 March 2015 worth over $360,430. On average, Charles trades about 1,016 units every 69 days since 2010. As of 3 June 2024 he still owns at least 47,137 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Wagner stock trades at the bottom of the page.
Charles F. (Charlie) Wagner has been appointed as Chief Financial Officer, Executive Vice President of the company. Effective April 10, 2019. Mr. Wagner joins Vertex from Ortho Clinical Diagnostics, Inc. – a Carlyle Group portfolio company, where he served as CFO and EVP, Finance. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, global information systems, lender relations, and acquisitions and divestitures, as well as shared responsibility for several enterprise-wide projects. Prior to this, Mr. Wagner served as CFO for publicly- traded Bruker Corporation, Progress Software Corporation and Millipore Corporation. In addition to his corporate finance roles, Mr. Wagner served as an advisor at Bain & Company and Coopers & Lybrand. He received his BS in accounting from Boston ` and his MBA from Harvard Business School.
As the Chief Financial Officer and Executive Vice President of Vertex Pharmaceuticals, the total compensation of Charles Wagner at Vertex Pharmaceuticals is $3,487,210. There are 7 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
Charles Wagner is 48, he's been the Chief Financial Officer and Executive Vice President of Vertex Pharmaceuticals since 2019. There are 19 older and 4 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O THE TJX COMPANIES, INC., 770 COCHITUATE RD., FRAMINGHAM, MA, 01701.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden, and Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: